|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0000744,
umls-concept:C0007634,
umls-concept:C0023418,
umls-concept:C0080279,
umls-concept:C0086418,
umls-concept:C0812385,
umls-concept:C1171350,
umls-concept:C1412097,
umls-concept:C1515655,
umls-concept:C1826328,
umls-concept:C2266681
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1999-2-9
|
|
pubmed:abstractText |
The leukemia cells of approximately 95% of patients with chronic myeloid leukemia and 30%-50% of adult patients with acute lymphoblastic leukemia express the Bcr/Abl oncoprotein, which is the product of a fusion gene created by a chromosomal translocation [(9:22) (q34;q11)]. This oncoprotein expresses a constitutive tyrosine kinase activity that is crucial for its cellular transforming activity. In this study, we evaluated the antineoplastic activity of CGP57148B, which is a competitive inhibitor of the Bcr/Abl tyrosine kinase.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0027-8874
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
163-8
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:9923858-Animals,
pubmed-meshheading:9923858-Antineoplastic Agents,
pubmed-meshheading:9923858-Enzyme Inhibitors,
pubmed-meshheading:9923858-Fusion Proteins, bcr-abl,
pubmed-meshheading:9923858-Humans,
pubmed-meshheading:9923858-Leukemia, Experimental,
pubmed-meshheading:9923858-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:9923858-Mice,
pubmed-meshheading:9923858-Piperazines,
pubmed-meshheading:9923858-Protein-Tyrosine Kinases,
pubmed-meshheading:9923858-Pyrimidines,
pubmed-meshheading:9923858-Signal Transduction,
pubmed-meshheading:9923858-Tumor Cells, Cultured
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.
|
|
pubmed:affiliation |
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
